Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel.
Senneville E, Cuervo G, Gregoire M, Hidalgo-Tenorio C, Jehl F, Miro JM, Seaton A, Söderquist B, Soriano A, Thalhammer F, Pea F. Senneville E, et al. Among authors: gregoire m. Int J Antimicrob Agents. 2023 Nov;62(5):106960. doi: 10.1016/j.ijantimicag.2023.106960. Epub 2023 Aug 24. Int J Antimicrob Agents. 2023. PMID: 37633424 Free article.
Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
Hervochon C, Hennart B, Leroy AG, Corvec S, Boutoille D, Senneville É, Sotto A, Illes G, Chavanet P, Dubée V, Bleibtreu A, De Carné MC, Talarmin JP, Revest M, Castan B, Bellouard R, Dailly É, Allorge D, Dinh A, Le Turnier P, Gregoire M; Dalbavancin Pharmacokinetics (DALBAP) study group. Hervochon C, et al. Among authors: gregoire m. J Antimicrob Chemother. 2023 Dec 1;78(12):2919-2925. doi: 10.1093/jac/dkad331. J Antimicrob Chemother. 2023. PMID: 37864551
Suboptimal dalbavancin dosages in an adult with sickle-cell disease and glomerular hyperfiltration.
Abdellaoui S, Gregoire M, Dubert M, Cheminet G, Arlet JB, Lafont E. Abdellaoui S, et al. Among authors: gregoire m. J Antimicrob Chemother. 2023 Mar 2;78(3):851-852. doi: 10.1093/jac/dkad013. J Antimicrob Chemother. 2023. Retraction in: J Antimicrob Chemother. 2023 Nov 6;78(11):2786. doi: 10.1093/jac/dkad283. PMID: 36702764 Retracted. No abstract available.
Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis.
Bellouard R, Rambaud A, Delaunay C, Dailly É, Lecomte R, Deschanvres C, Leroy AG, Boutoille D, Le Turnier P, Grégoire M; Nantes Anti-Microbial Agents PK/PD (NAMAP) study group. Bellouard R, et al. Among authors: gregoire m. J Antimicrob Chemother. 2023 Apr 3;78(4):965-974. doi: 10.1093/jac/dkad030. J Antimicrob Chemother. 2023. PMID: 36760090
A multifaceted strategy to optimize pharmacokinetics of antimicrobial therapy in patients with hospital-acquired infections-a monocentre quality improvement project.
Lagarde C, Bouras M, Le Floch R, Hourmant Y, Grillot N, Bourdiol A, Mahe PJ, Demeure Dit Latte D, Gregoire M, Dailly E, Bellouard R, Asehnoune K, Cinotti R, Roquilly A. Lagarde C, et al. Among authors: gregoire m. J Antimicrob Chemother. 2023 Jun 1;78(6):1378-1385. doi: 10.1093/jac/dkad094. J Antimicrob Chemother. 2023. PMID: 37042344
Development and validation of a dosing nomogram for amoxicillin in infective endocarditis.
Rambaud A, Gaborit BJ, Deschanvres C, Le Turnier P, Lecomte R, Asseray-Madani N, Leroy AG, Deslandes G, Dailly É, Jolliet P, Boutoille D, Bellouard R, Gregoire M; Nantes Anti-Microbial Agents PK/PD (NAMAP) study group. Rambaud A, et al. Among authors: gregoire m. J Antimicrob Chemother. 2020 Oct 1;75(10):2941-2950. doi: 10.1093/jac/dkaa232. J Antimicrob Chemother. 2020. PMID: 32601687
Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: phenotypic and genomic characterization.
Ruffier d'Epenoux L, Barbier P, Fayoux E, Guillouzouic A, Lecomte R, Deschanvres C, Nich C, Bémer P, Grégoire M, Corvec S. Ruffier d'Epenoux L, et al. Among authors: gregoire m. JAC Antimicrob Resist. 2024 Oct 18;6(5):dlae163. doi: 10.1093/jacamr/dlae163. eCollection 2024 Oct. JAC Antimicrob Resist. 2024. PMID: 39429235 Free PMC article.
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Deschanvres C, Reynes J, Lamaury I, Rey D, Palich R, Bani-Sadr F, Robineau O, Duvivier C, Hocqueloux L, Cuzin L, Joly V, Raffi F, Cabie A, Allavena C; Dat’AIDS Study Group. Deschanvres C, et al. J Antimicrob Chemother. 2021 Dec 24;77(1):196-204. doi: 10.1093/jac/dkab367. J Antimicrob Chemother. 2021. PMID: 34651192
549 results